Cambridge Investment Research Advisors
INSM icon

Cambridge Investment Research Advisors’s Insmed INSM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,719
Closed -$445K – 4108
2026
Q1 		$445K Sell
2,719
-672
-20% -$103K ﹤0.01% 2910
2025
Q4 		$590K Buy
3,391
+354
+12% +$64.6K ﹤0.01% 2562
2025
Q3 		$437K Buy
+3,037
New +$372K ﹤0.01% 2792

Other funds holding INSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Cambridge Investment Research Advisors's INSM Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Insmed (INSM) in Q2 2026, closing a stake of 2,719 shares — an estimated $445K sold.

Cambridge Investment Research Advisors first reported a position in INSM in Q3 2025 and held it in 3 quarters. The position peaked at $590K in Q4 2025. 663 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • Cambridge Investment Research Advisors reported no remaining Insmed position as of Q2 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 2,719 Insmed shares in Q2 2026, an estimated $445K.
  • Cambridge Investment Research Advisors first reported a position in Insmed in Q3 2025 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Insmed position peaked at $590K in Q4 2025.
  • 663 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.